



Ko42895 Page 10f3

NOV 1 6 2004

3. 510(k) Summary:

Sponsor:

Synthes (USA)

1690 Russell Road Paoli, PA 19301 (610) 647-9700

Contact:

Sheri L. Musgnung

Device Name:

Synthes LCP® Dynamic Helical Hip System, Additional Helix

Blades

Device Classification:

21 CFR 888.3030 - "Single/multiple component metallic bone

fixation appliances and accessories"

Predicate Device:

Synthes LCP® Dynamic Helical Hip System

Description of Device:

Synthes LCP Dynamic Helical Hip System is a plate and screw system

that consists of a straight plate with an angled barrel that accepts a helical blade. Synthes Helical blades, ranging in lengths from 135

mm to 150 mm are to be added to this system

Indications:

Synthes LCP® Dynamic Helical Hip System is intended to treat stable

and unstable intertrochanteric, subtrochanteric and basilar neck fractures in which a stable medial buttress can be reconstructed.

Material:

Stainless Steel

Substantial Equivalence:

Documentation is provided which demonstrates that the Synthes LCP

Dynamic Helical Hip System, additional Helix Blades is substantially

equivalent to other legally marketed Synthes devices.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 1 6 2004

Ms. Sheri L. Musgnung Regulatory Affairs Specialist Synthes (USA) 1690 Russell Road P.O. Box 1766 Paoli, Pennsylvania 19301-0800

Re: K042895

Device Name: Synthes (USA) LCP® Dynamic Helical Hip System (LCP DHHS), Additional

Helix Blades

Regulation Number: 21 CFR 888.3030

Regulation Name: Single, multiple component metallic bone fixation appliances and

accessories

Regulatory Class: II Product Code: KTT Dated: October 29, 2004

Received: November 1, 2004

Dear Ms. Musgnung:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2.	Indications for Use		
		Page1 of1	
	510(k) Number (if known):	Κœ	4 2 8 9 5
	Device Name:	Synthes (USA) LCP® Dynamic Helical Hip System (LCP DHHS), Additional Helix Blades	
	Indications for Use:	To treat stable and unstable intertrochanteric, subtrochanteric and basilar neck fractures in which a stable medial buttress can be reconstructed.	
	escription Use <u>X</u> er 21 CFR 801.109)	OR	Over-The-Counter Use
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off)			

Division of General, Restorative,

and Neurological Devices

TIO(k) Number_

000004